Middle East respiratory syndrome-related coronavirus

Roche announces the filing for FDA Emergency Use Authorization for SARS-CoV-2 Rapid Antigen Test, allowing healthcare professionals to make fast decisions at the point of care

Retrieved on: 
Monday, February 8, 2021
Medical tests, Branches of biology, Natural sciences, Medicine, Biotechnology, Medical terminology, Rapid antigen test, Polymerase chain reaction, Severe acute respiratory syndrome-related coronavirus, Middle East respiratory syndrome-related coronavirus

The test is designed to help healthcare professionals quickly identify a SARS-CoV-2 infection, typically in 15 minutes, in people exhibiting symptoms of the virus.

Key Points: 
  • The test is designed to help healthcare professionals quickly identify a SARS-CoV-2 infection, typically in 15 minutes, in people exhibiting symptoms of the virus.
  • The test is highly beneficial where timely decisions are needed and PCR tests are not readily available.
  • "This new rapid antigen test will provide a much needed resource to the healthcare system, as broad access to testing will be critical for re-opening our society."
  • This test will be a valuable addition to the comprehensive Roche diagnostic portfolio to help healthcare systems combat COVID-19 through testing in the laboratory and at the point of care.

Cocrystal Pharma Announces the Publication by Collaborators of Positive Data Demonstrating Potent In Vitro Inhibition Against Coronavirus in Science Translational Medicine Journal

Retrieved on: 
Tuesday, August 4, 2020
Zoonoses, Animal diseases, Veterinary medicine, Virology, Sarbecovirus, Antivirals, Animal virology, Coronavirus, Severe acute respiratory syndrome coronavirus, Middle East respiratory syndrome-related coronavirus, Translational medicine, 3CLpro-1

The manuscript titled, The 3C-like protease inhibitors with potent in-vitro inhibition against SARS-CoV-2 and therapeutic efficacy in MERS-CoV infected mice , was published online in the 3 August 2020 Science Translational Medicine Journal.

Key Points: 
  • The manuscript titled, The 3C-like protease inhibitors with potent in-vitro inhibition against SARS-CoV-2 and therapeutic efficacy in MERS-CoV infected mice , was published online in the 3 August 2020 Science Translational Medicine Journal.
  • To have this compelling data included in the prestigious publication, Science Translational Medicine, is a testament to the potential of these inhibitors to treat COVID-19.
  • The potent activity and the effectiveness of the mechanism of action demonstrated by these coronavirus protease inhibitors is very encouraging.
  • Science Translational Medicine is a weekly journal devoted to research and issues of strong interest to the translational medicine community.

NC Biotech Files Second Accelerated Patent to Combat Coronavirus Epidemic Using Microbiocidal Nanomaterials

Retrieved on: 
Tuesday, July 21, 2020
Health, Animal diseases, Zoonoses, Medical specialties, Bat virome, Sarbecovirus, COVID-19, Epidemiology, Coronavirus disease, Severe acute respiratory syndrome, Middle East respiratory syndrome-related coronavirus, Zoonosis

When treated, reusable materials would remain microbiocidal after repeated laundering with respect to an ever-evolving array of viruses, fungi, and bacteria, such as SARS-CoV-2, the zoonotic novel coronavirus that causes COVID-19.

Key Points: 
  • When treated, reusable materials would remain microbiocidal after repeated laundering with respect to an ever-evolving array of viruses, fungi, and bacteria, such as SARS-CoV-2, the zoonotic novel coronavirus that causes COVID-19.
  • In contrast, this invention would provide a hydrophilic surface of microbiocidal fullerenes that would bind and inactivate pathogens.
  • This patent is entitled, "Synthetic, multifaceted halogenated, functionalized fullerenes engineered for microbiocidal effects employing controlled contact for safe therapeutic and environmental utility."
  • Kepley BioSystems is a North Carolina-based biotech with a mission to emerge disruptive innovations to achieve global solutions.

Interferon Treatment Trial 'a Major Breakthrough' Against the Pandemic

Retrieved on: 
Tuesday, July 21, 2020
Respiratory diseases, Animal diseases, Medical specialties, Zoonoses, Bat virome, In Saudi Arabia, Merbecovirus, Sarbecovirus, Middle East respiratory syndrome-related coronavirus, Severe acute respiratory syndrome, Coronavirus disease, Coronavirus

Now, the preliminary results of a clinical trial by a UK biotech have confirmed the premise advocated by the Company, suggesting that an interferon inhalation treatment for COVID-19 reduces the number of patients needing intensive care.

Key Points: 
  • Now, the preliminary results of a clinical trial by a UK biotech have confirmed the premise advocated by the Company, suggesting that an interferon inhalation treatment for COVID-19 reduces the number of patients needing intensive care.
  • In the UK study, the treatment was delivered through a nebulizer and inhaled directly into the lungs of patients with coronavirus.
  • The treatment in the study used interferon beta, as opposed to the patent-pending interferon alpha 2b (IFN-a2b) treatment developed by BetterLife called AP-003.
  • Interferon treatments have been studied against coronaviruses including MERS-CoV, SARS-Cov-1 and now SARS-CoV-2 (the causative agent of COVID-19).

Promega Maxwell RNA Extraction System Authorized for Use in CDC COVID-19 Emergency Use Authorization (EUA) Diagnostic Panel

Retrieved on: 
Thursday, July 16, 2020
Medical Supplies, Health, FDA, Infectious diseases, Hospitals, Pharmaceutical, Molecular biology, Branches of biology, Natural sciences, Biochemistry, Laboratory techniques, Polymerase chain reaction, Promega, Reverse transcription polymerase chain reaction, Real-time polymerase chain reaction, Nucleic acid methods, Middle East respiratory syndrome-related coronavirus

Promega Corporations Maxwell RSC 48 Instrument and Maxwell RSC Viral Total Nucleic Acid Purification Kit (Maxwell Extraction System) are now in the Centers for Disease Control and Preventions (CDC) COVID-19 diagnostic protocol for emergency use.

Key Points: 
  • Promega Corporations Maxwell RSC 48 Instrument and Maxwell RSC Viral Total Nucleic Acid Purification Kit (Maxwell Extraction System) are now in the Centers for Disease Control and Preventions (CDC) COVID-19 diagnostic protocol for emergency use.
  • In a letter dated July 13, 2020, the U.S. Food and Drug Administration (FDA) authorized an amendment to the CDCs 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel stating the Promega Maxwell Extraction System is an authorized solution for laboratories that use the testing protocol.
  • View the full release here: https://www.businesswire.com/news/home/20200716005217/en/
    The Promega Maxwell RSC 48 Instrument and Maxwell RSC Viral Total Nucleic Acid Purification Kit are now authorized RNA extraction options in the Centers for Disease Control and Preventions (CDC) COVID-19 diagnostic protocol for emergency use.
  • The Promega GoTaq Probe 1-Step RT-qPCR System is also authorized for use in the CDCs 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel for emergency use.

As COVID Spreads, StateRecords Focuses on Single-Source Information

Retrieved on: 
Thursday, July 16, 2020
Viruses, Veterinary medicine, Zoonoses, Animal virology, Coronaviridae, In Saudi Arabia, Middle East respiratory syndrome, Coronavirus, Middle East respiratory syndrome-related coronavirus

Maryland.Staterecords.orgis covering all breaking news as well as providing statistics on the ongoing spread of the novel coronavirus.

Key Points: 
  • Maryland.Staterecords.orgis covering all breaking news as well as providing statistics on the ongoing spread of the novel coronavirus.
  • The outbreak is ongoing, and the need for consistent, reliable numbers is important for decision-making amongst the public.
  • Relaying on a single source for all information related to the virus - in this case the county governments of Maryland - can be an effective way to keep information consistent.
  • This organization also shares useful tips and advice on where to look for and access this information, as well as methods to avoid when trying to do so.

Todos Medical Announces ANVISA Authorization in Brazil for 3D Med qPCR Kits and ANDis Extraction S

Retrieved on: 
Thursday, July 16, 2020
Viruses, Animal diseases, OTC Markets Group, Middle East respiratory syndrome-related coronavirus, Veterinary medicine

On July 10, 2020, Todos Medical announced the expansion of its agreement with 3D Med to include COVID-19 testing product distribution rights in multiple international markets including Brazil, as well as in the U.S.

Key Points: 
  • On July 10, 2020, Todos Medical announced the expansion of its agreement with 3D Med to include COVID-19 testing product distribution rights in multiple international markets including Brazil, as well as in the U.S.
    For information related to Todos Medicals COVID-19 testing capabilities, please visit www.todoscovid19.com .
  • Headquartered in Rehovot, Israel, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers.
  • Todos has entered into distribution agreements with companies to distribute certain novel coronavirus (COVID-19) test kits.
  • For a more detailed description of the risks and uncertainties affecting Todos Medical, please refer to its reports filed from time to time with the U.S. Securities and Exchange Commission.

Integral Molecular Expands its Reporter Virus Technology to Enable Broad Testing for Coronavirus Protection Against Emerging Strains Including D614G

Retrieved on: 
Tuesday, July 14, 2020
Viruses, Zoonoses, Coronaviridae, Animal virology, Severe acute respiratory syndrome-related coronavirus, Severe acute respiratory syndrome, Coronavirus, Vaccine, Middle East respiratory syndrome-related coronavirus, Betacoronavirus

These variants will test the breadth of protection afforded by COVID-19 therapeutics and vaccines against newly emerging or resistant strains of the virus.

Key Points: 
  • These variants will test the breadth of protection afforded by COVID-19 therapeutics and vaccines against newly emerging or resistant strains of the virus.
  • Virus neutralization testing using RVPs is being adopted by vaccine companies for screening sera from clinical trials to provide rapid and safe testing under standard BSL-2 laboratory conditions.
  • Viruses mutate and change over time and these mutations can compromise the efficacy of drugs or vaccines through resistance.
  • SARS-CoV-2 is closely related to other coronaviruses that also cause severe illnesses, including SARS (severe acute respiratory syndrome) and MERS (Middle East respiratory syndrome) virus.

New England Biolabs' SARS-CoV-2 Rapid Colorimetric LAMP Assay Kit Enables Visual Detection of Novel Coronavirus In 30 Minutes

Retrieved on: 
Friday, July 10, 2020
Viruses, Nidovirales, Zoonoses, Coronaviridae, Laboratory techniques, Health in Saudi Arabia, In Saudi Arabia, Middle East respiratory syndrome-related coronavirus, Coronavirus, Severe acute respiratory syndrome-related coronavirus, Severe acute respiratory syndrome, CoV

IPSWICH, Mass., July 10, 2020 /PRNewswire/ --New England Biolabs (NEB) today announced the launch of the SARS-CoV-2 Rapid Colorimetric LAMP Assay Kit, a Research Use Only (RUO) product that can be used for the detection of novel coronavirus, SARS-CoV-2 RNA.

Key Points: 
  • IPSWICH, Mass., July 10, 2020 /PRNewswire/ --New England Biolabs (NEB) today announced the launch of the SARS-CoV-2 Rapid Colorimetric LAMP Assay Kit, a Research Use Only (RUO) product that can be used for the detection of novel coronavirus, SARS-CoV-2 RNA.
  • The kit serves as a simple alternative to RT-qPCR and enables visual detection of amplification of SARS-CoV-2 nucleic acid in just 30 minutes.
  • "With the SARS-CoV-2 Rapid Colorimetric LAMP Assay Kit, all you need is a simple heat source and 30 minutes to visually detect amplification of SARS CoV-2 RNA.
  • NEB,NEW ENGLAND BIOLABS, and WarmStart are registered trademarks of New England Biolabs, Inc.
    View original content to download multimedia: http://www.prnewswire.com/news-releases/new-england-biolabs-sars-cov-2-r...

Hilltop Holdings Inc. Announces Change in Location of the 2020 Annual Meeting of Stockholders to a Virtual-Only Format

Retrieved on: 
Thursday, July 9, 2020
Banking, Professional services, Finance, Shareholders, Viruses, Meetings, Animal diseases, Proxy statement, Statements, Proxy, Middle East respiratory syndrome-related coronavirus, Annual general meeting, Articles

Hilltop Holdings Inc. (NYSE: HTH) (Hilltop) determined that, due to public health and safety concerns related to the novel coronavirus (COVID-19) pandemic, the location of Hilltops 2020 Annual Meeting of Stockholders (the Annual Meeting) has been changed to a virtual-only format.

Key Points: 
  • Hilltop Holdings Inc. (NYSE: HTH) (Hilltop) determined that, due to public health and safety concerns related to the novel coronavirus (COVID-19) pandemic, the location of Hilltops 2020 Annual Meeting of Stockholders (the Annual Meeting) has been changed to a virtual-only format.
  • As previously announced, the Annual Meeting will be held on Thursday, July 23, 2020, at 10:00 a.m., Dallas, Texas local time.
  • Voting now at www.proxyvote.com will ensure your representation at the Annual Meeting regardless of whether you participate in the Annual Meeting.
  • The Proxy Statement for the Annual Meeting and the Annual Report to Stockholders for the fiscal year ended December 31, 2019 are available at www.proxyvote.com .